Skip to content

Vor Biopharma VOR Common Stock

Common Stock at other companies

Amgen logo
AmgenAMGN
2.8B0.0%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$54K+68.8%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$6K0.0%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
$6K0.0%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
200M0.0%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
390M+30.0%

Other financials

Income statement

See full
Operating income-$35.2M-5.6%
Net income-$219.6M-576%
EPS (diluted)-$5.11+1.9%

Balance sheet

See full
Cash & equivalents$169.9M+239%
Total debt$2.9M-90.5%
Total equity-$150.4M-328%
Total assets$506.7M+364%

Cash flow

See full
Operating cash flow-$38.2M-23.1%
CapEx$48.0K-79.2%
Free cash flow-$38.3M-22.4%

Valuation

See full
Market cap$784.61M+2,513%
Enterprise value$617.68M+5,639%

Returns & leverage

See full
Return on equity-125.4%+671pp
Debt / equity0.5×+0.2×
Current ratio31.1×+27.3×

Where this comes from

Reported directly by Vor Biopharma in its filing.

Tagged under the XBRL concept us-gaap:CommonStockValue.

The official record: Vor Biopharma’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vor Biopharma's common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vor Biopharma's common stock?
Vor Biopharma (VOR) reported common stock of $19K in Q1 2026.
How has Vor Biopharma's common stock changed year-over-year?
Vor Biopharma's common stock increased by 46.2% year-over-year, from $13K to $19K.
What is the long-term trend for Vor Biopharma's common stock?
Over 5 years (2020 to 2025), Vor Biopharma's common stock has grown at a 78.3% compound annual growth rate (CAGR), from $1K to $18K.
What does common stock mean?
The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).